WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/089043    International Application No.:    PCT/JP2007/052303
Publication Date: 09.08.2007 International Filing Date: 02.02.2007
A61K 9/127 (2006.01), A61K 31/282 (2006.01), A61K 31/337 (2006.01), A61K 31/513 (2006.01), A61K 31/537 (2006.01), A61K 31/573 (2006.01), A61K 31/7068 (2006.01), A61K 33/36 (2006.01), A61K 45/00 (2006.01), A61K 47/18 (2006.01), A61K 47/24 (2006.01), A61K 47/26 (2006.01), A61K 47/28 (2006.01), A61K 47/36 (2006.01), A61K 47/42 (2006.01), A61P 35/00 (2006.01)
Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410045 (JP) (For All Designated States Except US).
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY [JP/JP]; 3-1, Kasumigaseki 1-chome, Chiyoda-ku, Tokyo 1008921 (JP) (JP only).
YAMAZAKI, Noboru [JP/JP]; (JP) (For US Only).
YOSHIDA, Sei [JP/JP]; (JP) (For US Only).
YAMAOKA, Masuo [JP/JP]; (JP) (For US Only).
HORI, Akira [JP/JP]; (JP) (For US Only).
KAKIMOTO, Shigeya [JP/JP]; (JP) (For US Only).
FURUYA, Shuichi [JP/JP]; (JP) (For US Only)
Inventors: YAMAZAKI, Noboru; (JP).
YAMAOKA, Masuo; (JP).
HORI, Akira; (JP).
KAKIMOTO, Shigeya; (JP).
FURUYA, Shuichi; (JP)
Agent: KOBAYASHI, Hiroshi; c/o ABE, IKUBO & KATAYAMA Fukuoka Bldg. 9th Fl. 8-7, Yaesu 2-chome Chuo-ku, Tokyo 1040028 (JP)
Priority Data:
2006-027231 03.02.2006 JP
(JA) リポソーム製剤
Abstract: front page image
(EN)Disclosed is a cancer therapeutic preparation having an excellent targeting property. A sugar chain-modified liposome containing an aromatase inhibitor, an anti-androgenic agent, a lyase inhibitor, a GnRH agonist, a GnRH antagonist, an anti-angiogenic agent, a tyrosine kinase inhibitor, a serine-threonine kinase inhibitor, an antibody having an anti-cancer activity, ansamitocin, capecitabine, celmoleukin, docetaxel hydrate, gemcitabine hydrochloride, oxaliplatin, prednisolone, a tegafur-uracil blend, zinostatin stimalamer or arsenic trioxide or the like can be used as a cancer therapeutic preparation having an excellent targeting property or the like.
(FR)L'invention concerne une préparation thérapeutique visant à traiter un cancer et ayant une excellente propriété de vectorisation. L'invention concerne également un liposome avec une chaîne de sucre modifiée contenant un inhibiteur d'aromatase, un agent anti-androgénique, un inhibiteur de lyase, un agoniste de la GnRH, un antagoniste de la GnRH, un agent antiangiogenèse, un inhibiteur de tyrosine kinase, un inhibiteur de sérine-thréonine kinase, un anticorps ayant une action anticancéreuse, de l'ansamitocine, de la capécitabine, de la celmoleucine, un hydrate de docétaxel, un chlorhydrate de gemcitabine, de l'oxaliplatine, de la prednisolone, un mélange de tegafur et d'uracil, du zinostatine stimalamère ou du trioxyde d'arsenic, ou similaires, pouvant être utilisé en tant que préparation thérapeutique du cancer ayant une excellente propriété de vectorisation ou similaire.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)